You are here

Ceapro Announces Results of 2018 Shareholders’ Meeting

EDMONTON, Alberta, June 05, 2018 (GLOBE NEWSWIRE) -- Ceapro Inc.  (TSX-V:CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced today that all proposed Directors were elected to serve for a one-year term at its annual general and special meeting of shareholders held on May 29, 2018 as per following results:

Nominee                 Votes for  Votes withheld  % of votes cast
Glenn Rourke             14,547,962  366,358  97.54% 2.46%
Gilles Gagnon             14,318,305  596,015  96.00% 4.00%
Donald Oborowsky         14,434,462  479,858  96.78% 3.22%
John Zupancic           14,319,462  594,858  96.01% 3.99%
Dr. Ulrich Kosciessa     14,697,962  216,358  98.55% 1.45%
Dr. William Li          14,697,962 216,358 98.55% 1.45%

All other matters at the Shareholders' meeting, namely the appointment of auditors and the re-approval and ratification of the Company’s Stock Option Plan as proposed in the Company’s information circular dated April 18, 2018, were also approved by shareholders.

About Ceapro Inc.
Ceapro Inc. is a Canadian biotechnology company involved in the development of proprietary extraction technology and the application of this technology to the production of extracts and “active ingredients” from oats and other renewable plant resources. Ceapro adds further value to its extracts by supporting their use in cosmeceutical, nutraceutical and therapeutics products for humans and animals. The Company has a broad range of expertise in natural product chemistry, microbiology, biochemistry, immunology and process engineering. These skills merge in the fields of active ingredients, biopharmaceuticals and drug-delivery solutions. For more information on Ceapro, please visit the Company’s website at

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Jenene Thomas
Jenene Thomas Communications, LLC
T (US):  908-938-1475

Source:  Ceapro Inc.

Tuesday, June 5, 2018 - 09:00